All Reports Events Blogs Videos
Showing 11 results
  • NEW
    Blog
    Aug. 03, 2026

    In Part 1 of this series, Why the Migration Clock Has Already Started, we explained why Banking, Financial Services and Insurance (BFSI) enterprises cannot wait for a formal mandate to begin their Post-quantum Cryptography (PQC) migration and estimated a roughly US$7 billion spending opportunity across the top…
  • Blog
    July 29, 2026

    The pharmaceutical technology market is moving beyond point solutions. For years, providers competed by solving specific problems within individual parts of the value chain. Today, differentiation increasingly depends on how well those solutions can understand context,…
  • Blog
    July 21, 2026

    Current state of cryptography in BFSI  Banks, insurers, and capital markets enterprises have been using cryptography for a long time across every important part of their business. It protects everything from mobile payments to complex trading platforms and third-party connections.  …
  • Provider Recognition
    July 15, 2026

    Pharmaceutical enterprises are accelerating technology investments to modernize operations across the pharmaceutical value chain spanning drug discovery, clinical development, manufacturing, sales and marketing, supply chain and distribution, and pharmacovigilance. As AI, cloud, and data-driven capabilities become…
  • Roundtable
    April 16, 2026

    Following our GBS Operating Model FutureCast workshop, Everest Group is convening a select group of GBS leaders for an interactive working session on Thursday, May 07, to pressure test emerging perspectives on reimagining the operating model in the age of agentic AI.  …
  • Roundtable
    March 31, 2026

    Following our GBS Operating Model FutureCast workshop, Everest Group is convening a select group of GBS leaders for an interactive working session on Tuesday, April 14, to pressure test emerging perspectives on reimagining the operating model in the age of agentic AI.  …
  • Thematic Report
    March 26, 2026

    Pharmaceutical enterprises are reassessing their IT services sourcing strategies amid moderate growth, budget discipline, and rising innovation expectations. As provider consolidation intensifies, a small group of leading providers continues to capture a disproportionate share of enterprise…